# A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

> **NCT02827513** · PHASE1 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Adult Attention-deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** CTN SR1
- **DRUG:** CTN XR1
- **DRUG:** CTN XR2
- **DRUG:** CTN XR3

## Key facts

- **NCT ID:** NCT02827513
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02827513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02827513, "A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02827513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*